Analyzing Sofinnova Investments' Q3 vs. Q4 2022 13F Holdings: Winners and Losers

Sofinnova Investments is a renowned venture capital firm that invests in biotech and tech innovations. As per the latest 13F SEC filings, Sofinnova Investments had cumulative holdings of $2,082,509,000 in its portfolio for Q3 2022 and Q4 2022. This blog will provide a closer look at the Q3 and Q4 holdings of Sofinnova Investments and compare the percentage change between the two quarters.

Karuna Therapeutics Inc (KRTX) tops the list with 2073124 shares in Q3 2022, followed by Natera Inc (NTRA), having 3102960 shares in Q3 2022. Natera Inc (NTRA) experienced an 8.4% decrease in shares in Q4 2022 compared to Q3 2022, while Karuna Therapeutics Inc (KRTX) maintained its shareholdings.

Aerovate Therapeutics Inc (AVTE) was another winner, influencing Sofinnova Investments’ portfolio positively with a percentage increase of 76.7% in the value of its Q4 2022 holdings. Conversely, Cincor Pharma Inc (CINC) was a significant loser, with a percentage drop of 62.6% in the value of its Q4 2022 holdings compared to Q3 2022.

The pharmaceutical industry’s leading players, Sanofi SA (SNY) and Merck & Co Inc (MRK), also saw an increase of 98% and 33.2%, respectively, in the value of their Q4 2022 holdings compared to Q3 2022. Another pharmaceutical giant, AstraZeneca PLC (AZN), had an 8.1% increase in shares in Q4 2022.

On the other hand, Alnylam Pharmaceuticals Inc (ALNY) witnessed a drop in value in both Q3 and Q4 2022. It had no shares in Q4 2022 and held only 56448 shares in Q3 2022, resulting in a percentage drop of 100% in the Q4 2022 holdings.

In summary, the tables have turned for some companies between Q3 2022 and Q4 2022, with some experiencing tremendous growth and others losing their value. While Sofinnova Investments' Q4 2022 portfolio appears to have lowered in value, it still holds a diverse range of promising companies in the biotech and tech sector. Overall, this analysis demonstrates the volatility and unpredictability of the stock market, and it is always wise to keep track of the SEC filings to make informed investment decisions.